In the ITT population, ivonescimab demonstrated a clinically meaningful mPFS of 11.15 months vs. 5.82 months with pembrolizumab in 1L PD-L1 positive advanced NSCLC. ITT Stratified HR: Ivonescimab significantly reduced the risk of disease progression […]
Tag: Akeso
Ivonescimab (PD-1/VEGF) Received Priority Review from China’s NMPA for First-Line Treatment of PD-L1 Positive NSCLC
The Second Indication of Ivonescimab in NSCLC2L+ EGFRm NSCLC Already Approved in May 2024 HONG KONG, Aug. 14, 2024 /PRNewswire/ — Akeso, Inc. (HKEX: 9926.HK) (“Akeso,”) today announced that the National Center for Drug Evaluation […]
Two Ivonescimab (PD-1/VEGF) Results including Phase 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Treatment for PD-L1 Positive NSCLC to Be Presented at WCLC 2024
First Release of Phase III Head-to-Head Clinical Study Data of Ivonescimab versus Pembrolizumab in NSCLC Ivonescimab Is the First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab in a Randomized Phase III Clinical Trial in […]
